Intellia Therapeutics, Inc. (NTLA) Expected to Announce Quarterly Sales of $5.83 Million

Wall Street analysts predict that Intellia Therapeutics, Inc. (NASDAQ:NTLA) will announce sales of $5.83 million for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Intellia Therapeutics’ earnings, with the lowest sales estimate coming in at $5.00 million and the highest estimate coming in at $6.80 million. Intellia Therapeutics posted sales of $4.87 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 19.7%. The firm is scheduled to report its next earnings results on Tuesday, November 7th.

On average, analysts expect that Intellia Therapeutics will report full year sales of $5.83 million for the current fiscal year, with estimates ranging from $23.90 million to $35.70 million. For the next financial year, analysts expect that the firm will report sales of $40.00 million per share, with estimates ranging from $23.70 million to $56.30 million. Zacks’ sales calculations are a mean average based on a survey of analysts that cover Intellia Therapeutics.

Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Thursday, August 3rd. The company reported ($0.45) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by ($0.03). The firm had revenue of $5.90 million during the quarter, compared to analyst estimates of $5.83 million. Intellia Therapeutics had a negative net margin of 204.48% and a negative return on equity of 22.70%. The firm’s revenue for the quarter was up 40.5% compared to the same quarter last year.

A number of equities analysts have issued reports on the company. Oppenheimer Holdings, Inc. assumed coverage on Intellia Therapeutics in a research report on Tuesday, July 18th. They issued a “market perform” rating on the stock. TheStreet raised Intellia Therapeutics from a “d+” rating to a “c-” rating in a research report on Thursday, July 6th. Chardan Capital lowered Intellia Therapeutics from a “buy” rating to a “neutral” rating and set a $20.00 target price on the stock. in a research report on Tuesday, August 29th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $36.00 target price on shares of Intellia Therapeutics in a research report on Thursday, June 22nd. Finally, Cann reaffirmed a “hold” rating on shares of Intellia Therapeutics in a research report on Tuesday, August 1st. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Intellia Therapeutics currently has an average rating of “Hold” and an average target price of $26.80.

Institutional investors and hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC acquired a new position in shares of Intellia Therapeutics in the 2nd quarter valued at approximately $101,000. IHT Wealth Management LLC acquired a new stake in shares of Intellia Therapeutics during the 1st quarter valued at approximately $117,000. Bank of Montreal Can raised its position in shares of Intellia Therapeutics by 1,031.7% during the 2nd quarter. Bank of Montreal Can now owns 7,922 shares of the company’s stock valued at $127,000 after acquiring an additional 7,222 shares in the last quarter. Nationwide Fund Advisors raised its position in shares of Intellia Therapeutics by 117.7% during the 2nd quarter. Nationwide Fund Advisors now owns 8,048 shares of the company’s stock valued at $129,000 after acquiring an additional 4,351 shares in the last quarter. Finally, Nisa Investment Advisors LLC acquired a new stake in shares of Intellia Therapeutics during the 2nd quarter valued at approximately $134,000. 46.52% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Intellia Therapeutics, Inc. (NTLA) Expected to Announce Quarterly Sales of $5.83 Million” was first posted by Stock Observer and is owned by of Stock Observer. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright law. The legal version of this article can be read at https://www.thestockobserver.com/2017/10/13/intellia-therapeutics-inc-ntla-expected-to-announce-quarterly-sales-of-5-83-million.html.

Intellia Therapeutics (NTLA) opened at 29.28 on Friday. The stock’s market capitalization is $1.06 billion. The firm has a 50-day moving average of $25.65 and a 200 day moving average of $25.65. Intellia Therapeutics has a 52 week low of $10.83 and a 52 week high of $31.90.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.

Get a free copy of the Zacks research report on Intellia Therapeutics (NTLA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply